“Modeling Pharmacokinetics of Subcutaneous Nivolumab Doses for Phase III Evaluation”

https://pubmed.ncbi.nlm.nih.gov/38115195

This study developed a model to characterize the pharmacokinetics of subcutaneous nivolumab and predicted that a dose of 1200 mg SC every 4 weeks provides comparable exposures to approved and tested safe intravenous doses, informing the selection of this dose for phase III evaluation.